
Laboratory findings: In general, there were no clinically important influences of Candesartan on routine laboratory variables. As for other inhibitors of the renin-angiotensin-aldosterone system, small decreases in hemoglobin have been seen. No routine monitoring of laboratory variables is usually necessary for patients receiving Candesartan. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.
Treatment of Heart Failure: Table 2 presents adverse reactions of Candesartan. See Table 2.

Patient to seek medical attention immediately at the first sign of any adverse drug reaction shall appear.
View ADR Reporting Link